GDC-0032 is in a new class of cancer treatment drugs know as “targeted therapy”. The name refers to the fact that these drugs primarily focus on cancer cells, leaving healthy cells alone. For over 6 months, Lisa has been on a phase I clinical trial of GDC-0032 and it has kept her disease from progressing. One of the potential side effects of GDC-0032 is inflammation of the colon (colitis). Unfortunately for Lisa, this potential has become a reality.
Signs of colitis first appeared about three weeks ago and she was taken off the drug at that time. Since then, her abdominal pain and nausea has continued to worsen. Yesterday, she was admitted to MGH in order to get the situation under control. Thanks to pain meds and IV fluids she is resting much more comfortably. They have her on a no-food diet in order to rest her bowels.
As I write this, we are waiting for the specialist to show up and let us know what they have planed for her today.